Lifelong antiretroviral therapy or HIV cure: The benefits for the individual patient

被引:18
作者
Buell, Kevin G. [1 ]
Chung, Christopher [1 ]
Chaudhry, Zain [1 ]
Puri, Aiysha [1 ]
Nawab, Khizr [1 ]
Ravindran, Rahul Prashanth [1 ]
机构
[1] Univ London Imperial Coll Sci Technol & Med, Imperial Coll Sch Med, London SW7 2AZ, England
来源
AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV | 2016年 / 28卷 / 02期
关键词
HIV; stigma; pill burden; adherence; cure; INFECTED PATIENTS; SOCIAL STIGMA; ADHERENCE; AIDS; MEDICATION; DEPRESSION; HEALTH; CELLS; CCR5;
D O I
10.1080/09540121.2015.1074653
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
There are an estimated 35 million people living with human immunodeficiency virus (HIV) globally, 19 million of whom are unaware of their HIV status and, in the absence of antiretroviral therapy (ART), will have a shortened life expectancy. Although ART remains the gold standard for treatment of HIV infection, the requirement for lifelong treatment poses multiple challenges for the patient. These include stigma, an untenable pill burden, side effects, and the threat of viral resistance in the case of non-compliance. This review evaluates the challenges of accessing, delivering, and sustaining ART for people living with HIV and will discuss the case for pursuing a goal of HIV cure, the potential benefits of such a cure for the individual patient, and the current potential candidates for such a cure.
引用
收藏
页码:242 / 246
页数:5
相关论文
共 38 条
[1]   Effect of therapeutic intensification followed by HIV DNA prime and rAd5 boost vaccination on HIV-specific immunity and HIV reservoir (EraMune 02): a multicentre randomised clinical trial [J].
Achenbach, Chad J. ;
Assoumou, Lambert ;
Deeks, Steven G. ;
Wilkin, Timothy J. ;
Berzins, Baiba ;
Casazza, Joseph P. ;
Lambert-Niclot, Sidonie ;
Koup, Richard A. ;
Costagliola, Dominique ;
Calvez, Vincent ;
Katlama, Christine ;
Autran, Brigitte ;
Murphy, Robert L. .
LANCET HIV, 2015, 2 (03) :E82-E91
[2]  
[Anonymous], 2012, UNAIDS REP GLOB AIDS
[3]  
[Anonymous], 2014, GAP REP
[4]   Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy [J].
Archin, N. M. ;
Liberty, A. L. ;
Kashuba, A. D. ;
Choudhary, S. K. ;
Kuruc, J. D. ;
Crooks, A. M. ;
Parker, D. C. ;
Anderson, E. M. ;
Kearney, M. F. ;
Strain, M. C. ;
Richman, D. D. ;
Hudgens, M. G. ;
Bosch, R. J. ;
Coffin, J. M. ;
Eron, J. J. ;
Hazuda, D. J. ;
Margolis, D. M. .
NATURE, 2012, 487 (7408) :482-U1650
[5]  
Arhaus U. o., 2014, SAFETY EFFECT HDAC I
[6]   CD4+count and risk of non-AIDS diseases following initial treatment for HIV infection [J].
Baker, Jason V. ;
Peng, Grace ;
Rapkin, Joshua ;
Abrams, Donald I. ;
Silverberg, Michael J. ;
MacArthur, Rodger D. ;
Cavert, Winston P. ;
Henry, W. Keith ;
Neaton, James D. .
AIDS, 2008, 22 (07) :841-848
[7]   Mental health of HIV-infected patients: A severe, but Overlooked Problem [J].
Choi, Jun Yong .
INFECTION AND CHEMOTHERAPY, 2013, 45 (02) :239-240
[8]   IN-VIVO EMERGENCE OF HIV-1 VARIANTS RESISTANT TO MULTIPLE PROTEASE INHIBITORS [J].
CONDRA, JH ;
SCHLEIF, WA ;
BLAHY, OM ;
GABRYELSKI, LJ ;
GRAHAM, DJ ;
QUINTERO, JC ;
RHODES, A ;
ROBBINS, HL ;
ROTH, E ;
SHIVAPRAKASH, M ;
TITUS, D ;
YANG, T ;
TEPPLER, H ;
SQUIRES, KE ;
DEUTSCH, PJ ;
EMINI, EA .
NATURE, 1995, 374 (6522) :569-571
[9]   HIV Infection, Inflammation, Immunosenescence, and Aging [J].
Deeks, Steven G. .
ANNUAL REVIEW OF MEDICINE, VOL 62, 2011, 2011, 62 :141-155
[10]  
Department of Health, 2013, MAN HIV INF HEALTHC